{"id":"dose-dense-ac","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL4303689","moleculeType":"Small molecule","molecularWeight":"306.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen combines two DNA-damaging chemotherapy agents—doxorubicin (an anthracycline) and cyclophosphamide (an alkylating agent)—administered at increased doses with shortened intervals between cycles (typically every 2 weeks with growth factor support) rather than standard 3-week intervals. The dose-dense approach aims to improve efficacy by maintaining higher drug exposure and reducing the opportunity for tumor cell recovery between treatments.","oneSentence":"Dose-dense AC is a chemotherapy regimen that delivers doxorubicin and cyclophosphamide at higher doses over shorter intervals to maximize cytotoxic effect against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:28.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (adjuvant and neoadjuvant treatment)"},{"name":"High-risk early-stage breast cancer"}]},"trialDetails":[{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT07102940","phase":"PHASE2","title":"Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2026-05-01","conditions":"Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":50},{"nctId":"NCT05753618","phase":"PHASE4","title":"Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-04-17","conditions":"Early-stage Breast Cancer","enrollment":242},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT00861705","phase":"PHASE2","title":"Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-21","conditions":"Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7","enrollment":454},{"nctId":"NCT03283384","phase":"PHASE2","title":"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2019-06-15","conditions":"Breast Neoplasms","enrollment":100},{"nctId":"NCT02957968","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","status":"ACTIVE_NOT_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2017-01-24","conditions":"Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer","enrollment":46},{"nctId":"NCT05020860","phase":"PHASE2","title":"Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer","status":"RECRUITING","sponsor":"Baylor Breast Care Center","startDate":"2023-04-18","conditions":"Breast Cancer, Breast Neoplasm, Breast Cancer Female","enrollment":185},{"nctId":"NCT03493854","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-06-14","conditions":"Early Breast Cancer","enrollment":500},{"nctId":"NCT00499083","phase":"PHASE2","title":"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-05-01","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT00591851","phase":"PHASE2","title":"Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-12","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT03329378","phase":"PHASE2","title":"Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-01-24","conditions":"Locally Advanced Breast Cancer","enrollment":7},{"nctId":"NCT02489448","phase":"PHASE1, PHASE2","title":"Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-11","conditions":"Breast Neoplasms","enrollment":68},{"nctId":"NCT05580887","phase":"","title":"Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients","status":"UNKNOWN","sponsor":"Moscow Clinical Scientific Center","startDate":"2022-05-12","conditions":"Breast Cancer, Pancreas Cancer","enrollment":35},{"nctId":"NCT02789657","phase":"PHASE2","title":"Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.","status":"COMPLETED","sponsor":"Brown University","startDate":"2016-11-21","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT00546156","phase":"PHASE2","title":"Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer","status":"COMPLETED","sponsor":"Ian E. Krop, MD, PhD","startDate":"2007-10","conditions":"Breast Cancer","enrollment":104},{"nctId":"NCT00723125","phase":"PHASE2","title":"Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"William Sikov MD","startDate":"2008-09","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT00394251","phase":"PHASE2","title":"Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2006-08-01","conditions":"Breast Cancer","enrollment":197},{"nctId":"NCT01328249","phase":"PHASE2","title":"Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-03-03","conditions":"HER2-normal","enrollment":81},{"nctId":"NCT03876886","phase":"PHASE3","title":"The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-02-22","conditions":"Triple Negative Breast Cancer","enrollment":200},{"nctId":"NCT00681993","phase":"NA","title":"Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-04","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT03575520","phase":"PHASE2","title":"Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-06-07","conditions":"Breast Cancer","enrollment":63},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT02379585","phase":"PHASE1, PHASE2","title":"Fasting on Newly Diagnosed Breast Cancer","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2013-01","conditions":"HER2-positive Breast Cancer","enrollment":8},{"nctId":"NCT02527317","phase":"","title":"Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer","status":"COMPLETED","sponsor":"Beaumont Hospital","startDate":"2015-01","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT00093795","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-10","conditions":"Breast Cancer","enrollment":4894},{"nctId":"NCT02549534","phase":"","title":"Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-09","conditions":"Peripheral Neuropathy","enrollment":29},{"nctId":"NCT00482391","phase":"PHASE2","title":"Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-03","conditions":"Breast Cancer","enrollment":95},{"nctId":"NCT01498588","phase":"PHASE2","title":"Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2011-11","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":7},{"nctId":"NCT00201708","phase":"PHASE2","title":"Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2004-10","conditions":"Breast Cancer","enrollment":56},{"nctId":"NCT00436709","phase":"NA","title":"Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer","status":"UNKNOWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-07","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT01378533","phase":"PHASE3","title":"The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-05","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT00193115","phase":"PHASE2","title":"Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2004-03","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT00793377","phase":"PHASE3","title":"Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"","conditions":"Primary Breast Cancer","enrollment":913},{"nctId":"NCT00107094","phase":"PHASE1","title":"Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2005-03","conditions":"Breast Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["doxorubicin","cyclophosphamide","paclitaxel"],"phase":"marketed","status":"active","brandName":"Dose dense AC","genericName":"Dose dense AC","companyName":"Ottawa Hospital Research Institute","companyId":"ottawa-hospital-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dose-dense AC is a chemotherapy regimen that delivers doxorubicin and cyclophosphamide at higher doses over shorter intervals to maximize cytotoxic effect against cancer cells. Used for Breast cancer (adjuvant and neoadjuvant treatment), High-risk early-stage breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}